Cancer Therapy News and Research

RSS

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

WHO today published the new edition of its Model List of Essential Medicines which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others. The move opens the way to improve access to innovative medicines that show clear clinical benefits and could have enormous public health impact globally.

8 May 2015

Danish researchers discover way to map more than one protein at a time

Danish researchers at the University of Copenhagen have discovered how to map more than one protein at a time, when proteins repair damaged DNA. It is a discovery that will help accelerate the process of developing better and gentler cancer treatments.

8 May 2015

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

The World Health Organization (WHO) today published the new edition of its Model List of Essential Medicines) which includes ground-breaking new treatments for hepatitis C, a variety of cancers (including breast cancer and leukaemia) and multi-drug resistant tuberculosis (TB), among others...

8 May 2015

Quantitative phosphoproteomic approach to identify targeted cancer therapy

Winner of the Louise Eisenhardt Traveling Scholarship Award, Teresa Purzner, MD, presented her research, Quantitative Phosphoproteomics for Targeted Cancer Therapy.

7 May 2015

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

Heather Wakelee, MD, is the recipient of the 2015 ECOG-ACRIN Young Investigator Award, the ECOG-ACRIN Cancer Research Group announced today. Dr. Wakelee is associate professor of medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, Calif.

7 May 2015

CCM and MD Anderson partner to improve cancer care in China, Singapore

Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, announced today that it has signed a multi-year strategic development agreement with The University of Texas MD Anderson Cancer Center, an internationally renowned cancer research, treatment and education center.

6 May 2015

First patient receives new 'resistance-busting' experimental skin cancer drug

A patient has become the first to receive a new 'resistance-busting' experimental skin cancer drug with the launch of a phase I clinical trial. The patient has received a new panRAF inhibitor - a new type of drug under development to address the problem of drug resistance in advanced skin cancer and a number of other cancer types.

6 May 2015

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Acacia Pharma Ltd, a specialty pharmaceutical company developing supportive care products for post-surgical and cancer patients in the US and international markets, announces positive results from its Phase 2 study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

6 May 2015

Researchers study early response of cells to ischemia

A group of researchers from the Lomonosov Moscow State University in collaboration with their Irish colleagues from the University College Cork has studied the early response of cells to ischemia, which is a restriction in blood supply to tissues causing the death of the cell.

6 May 2015

Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).

6 May 2015

St. Jude scientists develop new computer tool to find DNA duplications and deletions in tumors

St. Jude Children's Research Hospital scientists have developed a significantly better computer tool for finding genetic alterations that play an important role in many cancers but were difficult to identify with whole-genome sequencing.

5 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Frederick Alt honored with 2015 Szent-Györgyi Prize for Progress in Cancer Research

Frederick Alt, PhD, director of the Program in Cellular and Molecular Medicine at Boston Children's Hospital, has been honored with the 2015 Szent-Györgyi Prize for Progress in Cancer Research.

4 May 2015

New discovery may change the principles for treating cancer

Danish researchers from the University of Copenhagen and Herlev Hospital have made a discovery that may change the principles for treating certain types of cancer.

30 Apr 2015

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer.

30 Apr 2015

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics Biotech Inc., a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the European Medicines Agency has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer.

29 Apr 2015

PCDx test performs better than FoundationOne test in clinical study

Data from a small cohort published OncoTargets and Therapy today shows that the Paradigm Cancer Diagnostic Test (PCDx) performed better than Foundation Medicine's FoundationOne test across a number of key clinical variables, including turnaround time (TAT) and clinically actionable biomarker targets.

28 Apr 2015

Research findings could offer new way to test for chemo brain in patients

UBC research shows that chemotherapy can lead to excessive mind wandering and an inability to concentrate. Dubbed 'chemo-brain,' the negative cognitive effects of the cancer treatment have long been suspected, but the UBC study is the first to explain why patients have difficulty paying attention.

28 Apr 2015

Molecular Health granted European patent for novel Erythropoietin receptor

Molecular Health announced today it has been granted a patent in Europe entitled "Tissue Protective Erythropoietin Receptor". This latest patent supports Molecular Health's discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth.

27 Apr 2015

Researchers move one step closer to developing effective radiotherapy for lung cancer

Radiotherapy using protons can deliver more accurate treatment to a tumour while reducing the dose to surrounding tissue. However, in mobile organs such as the lung, precise targeting of the dose is difficult. Now researchers have succeeded in making a model of breathing movement that allows for the precise measurement of narrow beams to a dummy tumour by simulating the motion and physical properties of the chest anatomy in a model, the 3rd ESTRO Forum in Barcelona, Spain, will hear today (Monday).

27 Apr 2015

Cancer Therapy News and Research

New edition of WHO Essential Medicines List includes new treatments for hepatitis C, cancers and multi-drug TB

Danish researchers discover way to map more than one protein at a time

WHO moves to improve access to lifesaving medicines for hepatitis C, Drug-resistant TB and cancers

Quantitative phosphoproteomic approach to identify targeted cancer therapy

Stanford University professor named recipient of 2015 ECOG-ACRIN Young Investigator Award

CCM and MD Anderson partner to improve cancer care in China, Singapore

First patient receives new 'resistance-busting' experimental skin cancer drug

Acacia Pharma reports positive results from APD403 Phase 2 study in CINV

Researchers study early response of cells to ischemia

Antigen-loaded porous silicon microparticles can boost effectiveness of breast cancer vaccines

St. Jude scientists develop new computer tool to find DNA duplications and deletions in tumors

Researchers identify multiple types of resistance to new targeted lung cancer drug

Frederick Alt honored with 2015 Szent-Györgyi Prize for Progress in Cancer Research

New discovery may change the principles for treating cancer

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

PCDx test performs better than FoundationOne test in clinical study

Research findings could offer new way to test for chemo brain in patients

Molecular Health granted European patent for novel Erythropoietin receptor

Researchers move one step closer to developing effective radiotherapy for lung cancer

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News